[Ser25] Protein Kinase C (19-31) Mechanistic Insights, Clini

[Ser25] Protein Kinase C (19-31): Mechanistic Insights, Clinical Applications, and Research Perspectives

Introduction
[Ser25] Protein Kinase C (19-31) is a synthetic peptide corresponding to amino acids 19-31 of the regulatory domain of Protein Kinase C (PKC), with a serine residue phosphorylated at position 25. PKC is a family of serine/threonine kinases that play pivotal roles in signal transduction pathways, regulating diverse cellular processes such as proliferation, differentiation, apoptosis, and immune responses (Newton, 2018, *Nat Rev Mol Cell Biol*). The [Ser25] modification is of particular interest due to its regulatory impact on PKC activity and downstream signaling.

Mechanistically, [Ser25] Protein Kinase C (19-31) acts as a competitive inhibitor of PKC by mimicking the autoinhibitory pseudosubstrate region. This peptide can bind to the catalytic domain of PKC, thereby preventing substrate phosphorylation and modulating PKC-mediated signaling cascades (House & Kemp, 1987, *Science*). The phosphorylated serine at position 25 further enhances its affinity and specificity for PKC isoforms, making it a valuable research tool for dissecting PKC-dependent pathways.

[Related: bleomycin] Clinical Value and Applications
The clinical significance of [Ser25] Protein Kinase C (19-31) arises from the central role of PKC in pathophysiological processes, including cancer, cardiovascular diseases, neurodegenerative disorders, and immune dysfunctions (Mellor & Parker, 1998, *Trends Biochem Sci*). Aberrant PKC activity has been implicated in tumorigenesis, metastasis, and chemoresistance, as well as in the progression of Alzheimer’s disease and diabetic complications (Griner & Kazanietz, 2007, *Nat Rev Cancer*).

By serving as a selective PKC inhibitor, [Ser25] Protein Kinase C (19-31) enables researchers to delineate the contribution of PKC signaling in disease models. In oncology, inhibition of PKC can suppress tumor cell proliferation, migration, and survival, offering a potential therapeutic strategy for malignancies with PKC overactivation (Antal et al., 2015, *J Cell Sci*). In neuroscience, modulating PKC activity has shown promise in ameliorating synaptic dysfunction and neuroinflammation associated with neurodegenerative diseases (Sun & Alkon, 2014, *J Neurochem*). Moreover, in immunology, PKC inhibition can attenuate inflammatory responses, suggesting utility in autoimmune and inflammatory disorders (Baier, 2003, *Immunol Rev*).

[Related: alfa amanitin] Key Challenges and Pain Points Addressed
Current pharmacological approaches targeting PKC are hindered by several challenges:
1. **Isoform Specificity:** Many small molecule PKC inhibitors lack selectivity among the various PKC isoforms, leading to off-target effects and toxicity (Steinberg, 2008, *J Clin Invest*).
2. **Cellular Permeability:** Peptide-based inhibitors often suffer from poor membrane permeability, limiting their intracellular efficacy.
3. **Pharmacokinetics:** Rapid degradation by proteases and short half-life in biological systems reduce the therapeutic potential of peptide inhibitors.
4. **Functional Redundancy:** The existence of multiple PKC isoforms with overlapping functions complicates the interpretation of inhibition studies.

[Ser25] Protein Kinase C (19-31) addresses some of these issues by providing a highly specific tool for PKC inhibition, particularly useful in in vitro and ex vivo studies. Its design, based on the endogenous regulatory sequence, confers greater selectivity and minimizes interference with unrelated kinases. The phosphorylated serine enhances binding affinity, improving inhibitory potency compared to non-phosphorylated analogs (House & Kemp, 1987, *Science*).

[Related: abt 263] Literature Review
A growing body of research supports the utility of pseudosubstrate peptides and their derivatives in PKC research:

1. **House, C. & Kemp, B.E. (1987). Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. *Science*, 238(4824), 1726-1728.**
This seminal study identified the pseudosubstrate region of PKC and demonstrated that synthetic peptides corresponding to this sequence can inhibit PKC activity in vitro.

2. **Griner, E.M. & Kazanietz, M.G. (2007). Protein kinase C and other diacylglycerol effectors in cancer. *Nat Rev Cancer*, 7(4), 281-294.**
The authors review the role of PKC in cancer and discuss the therapeutic potential of targeting PKC with selective inhibitors, including pseudosubstrate peptides.

3. **Antal, C.E. et al. (2015). Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. *J Cell Sci*, 128(20), 3456-3468.**
This study highlights the dual role of PKC isoforms in cancer and underscores the importance of isoform-selective modulation.

4. **Sun, M.K. & Alkon, D.L. (2014). Protein kinase C epsilon: a new molecular target for the treatment of Alzheimer's disease. *J Neurochem*, 129(4), 543-551.**
The authors discuss the neuroprotective effects of PKC modulation and the potential of PKC-targeted therapies in neurodegenerative diseases.

5. **Baier, G. (2003). The PKC gene module: molecular biosystematics to resolve its T cell functions. *Immunol Rev*, 192, 64-79.**
This review details the role of PKC isoforms in T cell activation and the implications for immune modulation.

6. **Newton, A.C. (2018). Protein kinase C: perfectly balanced. *Nat Rev Mol Cell Biol*, 19(7), 415-433.**
A comprehensive overview of PKC structure, regulation, and function, emphasizing the importance of precise modulation in health and disease.

7. **Steinberg, S.F. (2008). Structural basis of protein kinase C isoform function. *Physiol Rev*, 88(4), 1341-1378.**
This review provides insights into the structural determinants of PKC isoform specificity and the challenges in developing selective inhibitors.

Experimental Data and Results
Experimental studies utilizing [Ser25] Protein Kinase C (19-31) and related pseudosubstrate peptides have demonstrated their efficacy in modulating PKC activity in various cellular models. House & Kemp (1987) reported that the synthetic peptide corresponding to the PKC pseudosubstrate region inhibited PKC-mediated phosphorylation of histone and myelin basic protein in vitro, with IC50 values in the low micromolar range.

Subsequent studies have employed fluorescently labeled variants of the peptide to monitor PKC activity in live cells, confirming its ability to compete with endogenous substrates and attenuate PKC-dependent signaling events (Newton, 2018). In cancer cell lines, treatment with pseudosubstrate peptides resulted in reduced proliferation and increased apoptosis, supporting their utility as research tools for dissecting PKC function (Griner & Kazanietz, 2007).

In neuronal cultures, PKC inhibition by pseudosubstrate peptides has been shown to modulate synaptic plasticity and protect against excitotoxicity, suggesting potential applications in neurodegenerative disease models (Sun & Alkon, 2014). In immune cells, these peptides have been used to investigate the role of PKC in T cell activation and cytokine production, providing mechanistic insights into immune regulation (Baier, 2003).

Usage Guidelines and Best Practices
For optimal results, [Ser25] Protein Kinase C (19-31) should be used according to established protocols:

- **Preparation:** The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer (e.g., PBS) to the desired concentration. Stock solutions can be aliquoted and stored at -20°C to -80°C to prevent repeated freeze-thaw cycles.

- **Concentration:** Effective concentrations for in vitro studies typically range from 1 to 50 μM, depending on the cell type and experimental context. Titration experiments are recommended to determine the optimal inhibitory dose.

- **Delivery:** For cell-based assays, the peptide can be added directly to the culture medium. For improved cellular uptake, co-administration with cell-penetrating peptides (e.g., TAT sequence) or use of transfection reagents may be considered.

- **Controls:** Include appropriate negative controls (e.g., scrambled peptide or non-phosphorylated analog) to account for sequence-specific effects.

- **Assay Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 52 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11536852